ArticleInfectious diseases and therapy2025
Clinical and Virologic Outcomes of Baloxavir Compared with Oseltamivir in Pediatric Patients with Influenza in Japan.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis.Frontiers in microbiology · 2025Pooled it
- Pharmacokinetics, Safety, and Exploratory Efficacy of Onradivir in Children with Acute Uncomplicated Influenza: A Multicenter, Dose-Ranging, Phase 2 Study.Infectious diseases and therapy · 2026Article
- Baloxavir marboxil versus oseltamivir for influenza A in children aged 5 years and older: a community-based prospective cohort study.BMC infectious diseases · 2026Observational
- Efficacy and safety of baloxavir marboxil vs. oseltamivir in Chinese outpatients with influenza B: an IPTW-adjusted real-world cohort study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Observational
- Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice.Nature communications · 2026Article
- Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir Shares.Infectious diseases and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBaloxavir marboxil, a cap-dependent endonuclease inhibitor, has proven efficacy against influenza. There are limited comparative data between baloxavir and oseltamivir in Japanese pediatric patients with influenza. We evaluated the clinical and virologic outcomes and assessed safety of baloxavir compared with oseltamivir for treating influenza in Japanese patients aged 6 to < 12 years.
methodsIn this open-label, randomized (2:1) trial, patients received oral administration of either a single dose of baloxavir or a twice-daily 5-day course of oseltamivir. The primary efficacy endpoint was time to illness alleviation (TTIA). Other efficacy and safety endpoints were also assessed.
resultsOf 199 enrolled patients (mean age: 9 years), 195 were randomized (baloxavir, n = 128; oseltamivir, n = 67). Of these, 50.8% had influenza A/H3N2, 37.4% influenza B, and 10.3% influenza A/H1N1pdm. Median (95% confidence interval) TTIA was 44.8 (41.5, 69.7) h and 72.2 (50.9, 96.9) h in the baloxavir group and the oseltamivir group, respectively. The median time to first cessation of virus shedding was shorter in the baloxavir vs. oseltamivir group (48.0 vs. 192.0 h). Before treatment, one patient had PA/I38X virus infection at baseline. After treatment, PA/I38X viruses were observed in 12 patients (11 A/H3N2 and 1 A/H1N1pdm). No serious adverse events, including death, were observed in either group.
conclusionIn this study, baloxavir showed the potential for shortening of symptom duration compared with oseltamivir, which suggests baloxavir as an important treatment option for patients with influenza aged 6 to < 12 years.
trial registrationThe study was registered at the Japan Registry of Clinical Trial (jRCT) on November 11, 2020 (registration no. jRCTs011200011).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.